Experimental Drug Increased Lifespan in Animal Studies
Researchers demonstrated that a compound targeting the AMPK protein extended the lives of yeast, worms, and flies.
Updated on Sept. 29, 2026 in Life Sciences
Live Poll
Do you believe breakthroughs in animal aging research warrant high expectations for human clinical trials?
An experimental drug known as 991 has extended the lifespans of fission yeast, nematode worms, and fruit flies by up to 25 percent. The results, published in the journal Aging Cell, indicate the compound functions by activating the cellular energy-regulating protein AMPK.
Why it matters
AMPK acts as a critical biological fuel gauge that governs metabolism, inflammation, and cellular repair processes. Targeting this protein represents a strategy to manipulate the fundamental mechanisms of biological aging.
The drug 991 produced a maximum lifespan increase of 25 percent compared to control groups across three distinct model organisms. The compound specifically binds to and triggers the AMPK protein to initiate energy-conserving states.
The players
Medical Research Council
A United Kingdom-based public funding agency that supports biomedical research.
Aging Cell
A peer-reviewed scientific journal focusing on the biological mechanisms of aging.
The details
The drug 991 functions by directly binding to the AMPK protein—a metabolic sensor that regulates energy consumption within cells. By forcing the activation of this protein, the drug shifts cells into an energy-conserving state that appears to mitigate age-related decline. The study confirmed these results across fission yeast, nematode worms, and fruit flies.
Timeline
September 2026: Findings were published in the journal Aging Cell.
The Tech Race
This development aligns with broader efforts to identify pharmacological interventions for metabolic aging markers. It builds on previous research into the AMPK pathway as a primary target for extending healthy lifespan.
This drug is currently limited to laboratory research settings and does not have a timeline for clinical or human application. Future work will focus on whether these observed longevity effects can be replicated in mice.
The takeaway
The study validates a potential target for age-related research by successfully extending lifespan in multiple invertebrate models. Observers should track upcoming trials that shift these experiments into mouse models to determine if the 25 percent efficacy persists in more complex physiology.
Further reading
For more on the latest research in cellular mechanisms, visit Life Sciences.
Live Poll
Do you believe breakthroughs in animal aging research warrant high expectations for human clinical trials?
